SEC Form 4 filed by Chief Commerical Officer Stone Warren

$NEO
Precision Instruments
Health Care
Get the next $NEO alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stone Warren

(Last) (First) (Middle)
9490 NEOGENOMICS WAY

(Street)
FORT MYERS FL 33912

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commerical Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 84,822 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit $0 01/14/2025 A 59,382 01/13/2026 (1) Common Stock 59,382 $0 59,382 D
Stock Option (Right to Buy) $11.21 (2) 12/01/2029 Common Stock 166,113 166,113 D
Stock Option (Right to Buy) $19.65 (3) 05/11/2030 Common Stock 53,969 53,969 D
Restricted Stock Unit $0 (4) (1) Common Stock 19,226 19,226 D
Performance Stock Unit $0 05/11/2026(5) (1) Common Stock 21,204 21,204 D
Stock Option (Right to Buy) $16.45 (6) 02/23/2034 Common Stock 42,344 42,344 D
Restricted Stock Unit $0 (7) (1) Common Stock 25,329 25,329 D
Performance Stock Unit $0 02/23/2027(8) (1) Common Stock 25,330 25,330 D
Stock Option (Right to Buy) $13.96 (9) 05/02/2034 Common Stock 29,976 29,976 D
Restricted Stock Unit $0 (10) (1) Common Stock 17,908 17,908 D
Performance Stock Unit $0 05/02/2027(11) (1) Common Stock 17,908 17,908 D
Explanation of Responses:
1. Once vested, the shares of common stock are not subject to expiration.
2. On December 1, 2022, Mr. Stone was granted 166,113 stock options. These options vest ratably over the first four anniversary dates of the grant date.
3. On May 11, 2023, Mr. Stone was granted 53,969 stock options. These options vest ratably over the first three anniversary dates of the grant date.
4. On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
5. On May 11, 2023, Mr. Stone was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is31,806. The number of performance stock units that may vest is based on the achievement of certain growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
6. On February 23, 2024, Mr. Stone was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date.
7. On February 23, 2024, Mr. Stone was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
8. On February 23, 2024, Mr. Stone was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
9. On May 2, 2024, Mr. Stone was granted 29,976 stock options. These options vest ratably over the first three anniversary dates of the grant date.
10. On May 2, 2024, Mr. Stone was granted 17,905 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
11. On May 2, 2024, Mr. Stone was granted 17,908 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is26,862. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
Remarks:
/s/ Ali Olivo, Attorney-in-Fact 01/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $NEO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NEO

DatePrice TargetRatingAnalyst
1/13/2025Buy → Hold
The Benchmark Company
12/10/2024$22.00Buy
Jefferies
5/1/2024$26.00Buy
Craig Hallum
12/29/2023$25.00 → $21.00Buy
BTIG Research
8/21/2023$18.00Equal-Weight → Overweight
Stephens
5/16/2023Outperform → Mkt Perform
Raymond James
5/9/2023$25.00Neutral → Buy
BTIG Research
2/24/2023$20.00Hold → Buy
The Benchmark Company
More analyst ratings

$NEO
Press Releases

Fastest customizable press release news feed in the world

See more
  • NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

    Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f

    $NEO
    Precision Instruments
    Health Care
  • NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

    NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics' commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country. Founded in 2009, Pathline serves a long-standing client base of hospitals, cancer centers, and physician practices, with approximately 98% of its rev

    $NEO
    Precision Instruments
    Health Care
  • NeoGenomics to Participate in Upcoming Investor Conferences

    NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences: TD Cowen 45th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4 at 1:50 p.m. ET, accessible here Leerink Partners Global Healthcare Conference in Miami, FL Fireside chat on Tuesday, March 11 at 3:30 p.m. ET, accessible here Barclays 27th Annual Global Healthcare Conference in Miami, FL Fireside chat on Thursday, March 13 at 9:00 a.m. ET, accessible here Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company's websi

    $NEO
    Precision Instruments
    Health Care

$NEO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NEO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$NEO
SEC Filings

See more

$NEO
Leadership Updates

Live Leadership Updates

See more
  • NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

    Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f

    $NEO
    Precision Instruments
    Health Care
  • PacBio Announces Appointment of Chris Smith to Board of Directors

    MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in

    $NEO
    $PACB
    Precision Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Felicia Williams Joins NeoGenomics Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. "We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics," said Lynn Tetrault, Chairwoman of the Board of NeoGenomics. "We look forward to working together to support the company and improve patient care." The Board has elected Felicia Williams to join the Board as an independent director effective November 1, 2024. Felicia, former interim CFO of Macy's Inc. and Fellow for CEO Action for Racial Equa

    $NEO
    Precision Instruments
    Health Care

$NEO
Financials

Live finance-specific insights

See more
  • NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

    NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics' commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country. Founded in 2009, Pathline serves a long-standing client base of hospitals, cancer centers, and physician practices, with approximately 98% of its rev

    $NEO
    Precision Instruments
    Health Care
  • NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

    Full Year Revenue Increased 12% to $661 million; Ninth Consecutive Quarter of Double-Digit Revenue Growth NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter consolidated revenue increased 11% to $172 million; Full year consolidated revenue increased 12% to $661 million Fourth quarter net loss increased 7% to $15 million; Full year net loss decreased 11% to $79 million Fourth quarter adjusted EBITDA increased 27% to positive $12 million; Full year adjusted EBITDA increased 1,036% to

    $NEO
    Precision Instruments
    Health Care
  • NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

    NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (i

    $NEO
    Precision Instruments
    Health Care

$NEO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more